Corticosteroids Notes

Corticosteroids

Learning Objectives

  • Understand the basic concepts regarding the role of corticosteroids within the body.
  • Understand the different roles for clinical corticosteroid use including physiologic, anti-inflammatory, and immune suppression.
  • Learn about the different types of corticosteroids, route of administration, duration of action, and relative potency.
  • Recognize the adverse reactions and common side effects associated with corticosteroid use.
  • Identify common laboratory changes associated with corticosteroid use.

Definitions, Physiology, and Mechanism of Action

Introduction

Basic Definitions

  • Corticosteroids: Class of chemicals produced by the adrenal cortex including the steroid hormones.
  • Two primary types of corticosteroids:
    • Glucocorticoids
    • Mineralocorticoids

Mineralocorticoids

  • Such as aldosterone, control electrolyte and water balance within the body.

Glucocorticoids

  • Such as cortisol and cortisone are important in control of carbohydrate, fat, and protein metabolism.
  • Augmentation of the immune and inflammatory systems.
  • Have many other mechanisms within the body.

Corticosteroid Physiology

  • Adrenal gland produces:
    • Mineralocorticoids
    • Sex hormones
    • Endogenous glucocorticoids
  • Adrenal cortex is comprised of three zones:
    • Zona glomerulosa
    • Zona reticularis
    • Zona fasciculata

Zona Glomerulosa

  • Superficial or outermost layer.
  • Secretion of mineralocorticoids.
  • Aldosterone: important in the regulation of electrolytes (sodium and potassium) and water balance within the body.

Zona Reticularis

  • Sex hormones, predominately the androgens.

Zona Fasciculata

  • Endogenous glucocorticoids cortisol and cortisone.

Hypothalamopituitary Axis (HPA Axis)

  • Hypothalamus:
    • Corticotropin releasing hormone (CRH)
  • Pituitary:
    • Adrenocorticotropic hormone (ACTH)
  • Adrenal glands:
    • Glucocorticoids (cortisol and cortisone)
  • Negative Feedback by ACTH and Glucocorticoid

Normal HPA Axis

  • Hypothalamus releases CRH which stimulates the Pituitary to release ACTH. ACTH stimulates the Adrenal cortex to produce Cortisol. Cortisol then provides negative feedback to both the Hypothalamus and Pituitary.

HPA Axis with Exogenous Steroids

  • Exogenous steroids will cause a decrease in CRH and ACTH release by negative feedback.

Mechanism of Action

  • Complex.
  • Two primary types of corticosteroid receptors:
    • Type I mineralocorticoid receptors
    • Type II glucocorticoid receptors
  • Mineralocorticoids and glucocorticoids have varying degrees of affinity for both.

Type II Glucocorticoid Receptors

  • All cells in varying concentrations.
  • Up or down regulation.
  • Found within the cytoplasm.
  • Variety of actions:
    • Gene transcription
    • Protein induction or inhibition

Mechanism of Action Depends on Dose

  • Physiologic
  • Anti-inflammatory
  • Immunosuppression

Physiologic Effects in Health

  • Corticosteroids required for normal daily functions.
  • Stimulate formation of glucose by the liver.
  • Decrease peripheral utilization of glucose.
  • Promotes storage of glucose as glycogen.
  • Promote lipolysis:
    • Generates free fatty acids that serve as substrates for hepatic glycogen synthesis
  • Maintaining renal blood flow and glomerular filtration.
  • Maintaining normal vascular tone.
  • Glucocorticoids and mineralocorticoids are essential in maintaining water and electrolyte balance within the body.

Clinical Use of Corticosteroids

General Concepts of Mineralocorticoid and Glucocorticoid Use

Mineralocorticoids

  • Predominant use in treatment of Addison's disease (hypoadrenocorticism).
  • Addison’s Disease is a failure of the adrenal gland to produce aldosterone and/or glucocorticoids.
  • Two most common treatment options for mineralocorticoid replacement:
    • Fludrocortisone
    • Desoxycorticosterone pivalate (DOCP)

Fludrocortisone (Florinef)

  • Mineralocorticoid with some glucocorticoid activity.
  • Dosed in dogs initially at 0.01 to 0.02 mg per kilogram orally daily.
  • Monitored every 1 to 2 weeks
    • Dosage increased by small increments until desired effect achieved
  • Addition of a glucocorticoid may not be necessary.
  • Failure to respond or develop adverse effects of excessive glucocorticoid administration.
  • Rarely used anymore due to convenience and generally excellent response to DOCP.

Desoxycorticosterone Pivalate (DOCP; Percortin)

  • Mineralocorticoid, no glucocorticoid activity.
  • Initially administered as 2.2 mg per kilogram intramuscularly or subcutaneously every 25 days.
  • May be maintained on as low as 0.8 to 1 mg per kilogram and dosing intervals of 28 to 30 days.
  • Not tapered more than 10% per month.
  • Sodium and potassium concentration monitored at 28 to 30 days after administration.

Glucocorticoids

  • Several different clinical uses of glucocorticoids.
  • To better facilitate understanding, we are first going to focus on prednisone since it is the most common glucocorticoid used in veterinary medicine.
    • Physiologic glucocorticoid replacement
      • Prednisone range 0.25 to 0.5 mg/kg/day
    • Anti-inflammatory
      • Prednisone range 0.5 to 1 mg/kg/day
    • Immunosuppression
      • Prednisone range 2 to 4 mg/kg/day

Physiologic Glucocorticoid Replacement

  • Indicated when failure of adrenal gland to produce enough glucocorticoids for maintenance of routine daily functions.
  • Primarily indicated in three conditions:
    • Addison's disease (Hypoadrenocorticism)
    • Iatrogenic adrenal suppression
    • Relative Adrenal Insufficiency (RAI) or Critical Illness –Related Corticosteroid Insufficiency (CIRCI)
Iatrogenic Suppression
  • Occurs with chronic glucocorticoid therapy that is withdrawn too quickly.
  • Temporary supplementation and longer taper.
Relative Adrenal Insufficiency (RAI)
  • Critical Illness –Related Corticosteroid Insufficiency (CIRCI)
  • Relative adrenal insufficiency occurring secondary to critical illness and sepsis
  • Controversial topic as to significance
  • Prednisone dose ranges 0.25 - 0.5 mg/kg/day
  • Patients may need a slightly higher dose during perceived or anticipated times of stress

Anti-inflammatory Glucocorticoid

  • Indicated in sterile or idiopathic inflammatory processes and certain allergic conditions.
  • Prednisone dose range 0.5 – 1.0 mg/kg/day
  • Examples in which anti-inflammatory glucocorticoid use may be helpful include:
    • Atopy (Skin manifestations and otitis externa)
    • Allergic reactions
    • Feline asthma
    • Chronic bronchitis
    • Certain neurologic and ophthalmological inflammatory diseases
    • Airway swelling (acute exacerbations of tracheal collapse or laryngeal paralysis)

Immunosuppressive Glucocorticoids

  • Indicated in immune mediated diseases and in some cancer treatment protocols.
  • Treatment is typically extended
    • Secondary agent may be used to reduce glucocorticoid use and potential adverse effects
  • Prednisone dose 2 – 4 mg/kg/day
  • Examples in which immunosuppressive doses of glucocorticoids are indicated:
    • Immune mediated hemolytic anemia
    • Immune mediated thrombocytopenia
    • Inflammatory bowel disease (patients may be weaned down to lower anti-inflammatory doses)
    • Immune mediated polyarthropathy
    • Sterile immune mediated meningitis or meningoencephalitis
    • Part of a lymphoma treatment protocol

Selected Drugs and Preparations

Commonly Encountered Glucocorticoids

Prednisone and Prednisolone

  • Glucocorticoid with some mineralocorticoid activity.
  • Prednisone metabolized by liver to prednisolone.
  • Prednisolone is the active form.
  • Liver disease has minimal effect on metabolism.
  • Species variability in prednisone metabolism
    • Dogs- dosing considered equivalent between prednisone and the prednisolone
    • Cats- evidence suggests higher doses of prednisone (2 to 3 fold higher) required to achieve equivalent activity of prednisolone
    • Resources suggest using prednisolone in cats
  • Prednisone:
    • Only oral form
  • Prednisolone:
    • Oral
    • Injectable
    • Topical preparations

Dexamethasone

  • Highly potent glucocorticoid with virtually no mineralocorticoid activity
  • Most common injectable glucocorticoid
  • Does not interfere with ACTH stimulation testing for diagnoses of Addison's disease
  • Glucocorticoid of choice for management of suspected Addisonian crisis prior to ACTH stimulation testing
  • 7 to 10 times more potent than prednisone
  • Often used for acute management of diseases
    • Especially if not eating or vomiting
  • Available in oral, injectable, and topical forms

Methylprednisolone

  • Potency and mineralocorticoid activity similar to prednisone
  • Two most common forms:
    • Methylprednisolone sodium succinate
      • short acting form
    • Methylprednisolone acetate
      • longer acting form
  • Injectable preparations most common

Methylprednisolone Sodium Succinate

  • Solu-Medrol
  • Short duration, rapid onset
  • Indications
    • Acute spinal trauma (controversial)
    • Acute severe inflammatory or immune mediated CNS conditions

Methylprednisolone Acetate

  • Depo-Medrol
  • Longer acting repository glucocorticoid
  • Indications
    • Difficult to medicate patients
    • Certain allergic conditions
  • Dosing intervals
    • Depend on response and disease process
    • One week to several months
  • Used carefully or avoided in certain diseases
    • Feline asthma
    • Immune mediated processes
  • Refractory signs or exacerbation of disease
    • Too rapid withdrawal/lack of tapering

Budesonide

  • “Soft" glucocorticoid
    • Local activity
    • Once absorbed, rapidly metabolized by liver
  • Used orally in management of inflammatory bowel disease
    • Reduced adverse glucocorticoid effects
  • Some patients still develop adverse signs and HPA axis suppression
  • Found in oral, topical, and inhalant preparations

Corticosteroid Potency and Half-Lives

CorticosteroidGlucocorticoid PotencyMineral Corticoid PotencyBiological Half-Life (Hr)
Cortisol118-12
Hydrocortisone0.818-12
Prednisone40.812-36
Prednisolone40.812-36
Methylprednisolone50.512-36
Triamcinolone5+024-48
Dexamethasone25-50036-72
Betamethasone25-50036-72
Fludrocortisone10125-20012-36
Deoxycorticosterone020

Length of Treatment and Tapering Glucocorticoids

  • Use should be minimized and length of treatment be tailored to the specific disease process
    • Hypoadrenocorticism
      • May require lifelong therapy
    • Iatrogenic adrenal suppression or RAI
      • Taper performed over days to a few weeks
    • Acute allergic or inflammatory diseases expected to resolve quickly
      • Short courses, tapered over days to a couple of weeks
    • Chronic disease or immune mediated processes
      • Slowly tapered over several months
      • May require chronic therapy at lowest dose to control clinical signs
  • Patients intolerant to glucocorticoids or requiring long-term therapy may benefit from addition of secondary immunosuppressive agent

Adverse Effects of Corticosteroids

  • Glucocorticoids have an effect on virtually every cell type and system in mammals
  • Adverse effects range from minor "nuisance" to severe clinically significant side effects

"Nuisance" Adverse Effects

  • Polydipsia
  • Polyuria
  • Polyphagia
  • Panting

Clinically Significant Adverse Effects

  • Adverse effects more commonly observed with chronic therapy:
    • Steroid hepatopathy
    • Skin and hair coat changes (thinning of the skin, alopecia, ect..)
    • Decrease muscle mass and wasting
    • Fat accumulation
    • Altered mentation, behavior, energy
  • Adverse effects which may be associated with acute and chronic administration:
    • Gastrointestinal ulceration
    • Insulin resistance
    • Hypercoagulability, thromboembolism
    • Sodium and water retention leading to exacerbation of cardiac disease
    • Myopathies
    • Immune suppression

Laboratory Changes Associated with Glucocorticoid Use

Laboratory Changes

  • Serum chemistry profile
    • Increased ALP +/- ALT
    • Hypercholesterolemia
    • Hyperalbuminemia
    • Hyperglycemia
    • Increased amylase and lipase
  • Complete blood count
    • Thrombocytosis
    • Stress leukogram
    • Mild anemia
  • Urinalysis
    • Isosthenuria or hyposthenuria associated with PU/PD
    • Proteinuria
    • Decrease in pH

Primary Reference and Suggested Further Reading

  • Boothe, D and Mealey, K. Glucocorticoids and Mineralocorticoids. In: Boothe, editor. Small Animal Clinical Pharmacology and Therapeutics, Second Edition. Elsevier; 2012; pp. 1119-1149.